629 related articles for article (PubMed ID: 32470562)
1. Fecal bacteria can predict the efficacy of rifaximin in patients with diarrhea-predominant irritable bowel syndrome.
Li Y; Hong G; Yang M; Li G; Jin Y; Xiong H; Qian W; Hou X
Pharmacol Res; 2020 Sep; 159():104936. PubMed ID: 32470562
[TBL] [Abstract][Full Text] [Related]
2. Gut fungal dysbiosis and altered bacterial-fungal interaction in patients with diarrhea-predominant irritable bowel syndrome: An explorative study.
Hong G; Li Y; Yang M; Li G; Qian W; Xiong H; Bai T; Song J; Zhang L; Hou X
Neurogastroenterol Motil; 2020 Nov; 32(11):e13891. PubMed ID: 32449259
[TBL] [Abstract][Full Text] [Related]
3. Duodenal and rectal mucosal microbiota related to small intestinal bacterial overgrowth in diarrhea-predominant irritable bowel syndrome.
Yang M; Zhang L; Hong G; Li Y; Li G; Qian W; Xiong H; Bai T; Song J; Hou X
J Gastroenterol Hepatol; 2020 May; 35(5):795-805. PubMed ID: 31674052
[TBL] [Abstract][Full Text] [Related]
4. Double-Blind Placebo-Controlled Study of Rifaximin and Lactulose Hydrogen Breath Test in Gulf War Veterans with Irritable Bowel Syndrome.
Tuteja AK; Talley NJ; Stoddard GJ; Verne GN
Dig Dis Sci; 2019 Mar; 64(3):838-845. PubMed ID: 30370492
[TBL] [Abstract][Full Text] [Related]
5. [Clinical features of irritable bowel syndrome with small intestinal bacterial overgrowth and a preliminary study of effectiveness of Rifaximin].
Liu ZJ; Wei H; Duan LP; Zhu SW; Zhang L; Wang K
Zhonghua Yi Xue Za Zhi; 2016 Jun; 96(24):1896-902. PubMed ID: 27373356
[TBL] [Abstract][Full Text] [Related]
6. Fecal and Mucosa-Associated Intestinal Microbiota in Patients with Diarrhea-Predominant Irritable Bowel Syndrome.
Maharshak N; Ringel Y; Katibian D; Lundqvist A; Sartor RB; Carroll IM; Ringel-Kulka T
Dig Dis Sci; 2018 Jul; 63(7):1890-1899. PubMed ID: 29777439
[TBL] [Abstract][Full Text] [Related]
7. Short-course Rifaximin therapy efficacy and lactulose hydrogen breath test in Chinese patients with diarrhea-predominant irritable bowel syndrome.
Zhuang X; Tian Z; Luo M; Xiong L
BMC Gastroenterol; 2020 Jun; 20(1):187. PubMed ID: 32532214
[TBL] [Abstract][Full Text] [Related]
8. Fecal Microbiota Alterations Associated With Diarrhea-Predominant Irritable Bowel Syndrome.
Zhuang X; Tian Z; Li L; Zeng Z; Chen M; Xiong L
Front Microbiol; 2018; 9():1600. PubMed ID: 30090090
[TBL] [Abstract][Full Text] [Related]
9. Limited prolonged effects of rifaximin treatment on irritable bowel syndrome-related differences in the fecal microbiome and metabolome.
Zeber-Lubecka N; Kulecka M; Ambrozkiewicz F; Paziewska A; Goryca K; Karczmarski J; Rubel T; Wojtowicz W; Mlynarz P; Marczak L; Tomecki R; Mikula M; Ostrowski J
Gut Microbes; 2016 Sep; 7(5):397-413. PubMed ID: 27662586
[TBL] [Abstract][Full Text] [Related]
10. Rifaximin is associated with modest, transient decreases in multiple taxa in the gut microbiota of patients with diarrhoea-predominant irritable bowel syndrome.
Fodor AA; Pimentel M; Chey WD; Lembo A; Golden PL; Israel RJ; Carroll IM
Gut Microbes; 2019; 10(1):22-33. PubMed ID: 29708822
[TBL] [Abstract][Full Text] [Related]
11. Small intestinal bacterial overgrowth is associated with Diarrhea-predominant irritable bowel syndrome by increasing mainly
Wu KQ; Sun WJ; Li N; Chen YQ; Wei YL; Chen DF
Scand J Gastroenterol; 2019 Dec; 54(12):1419-1425. PubMed ID: 31765575
[No Abstract] [Full Text] [Related]
12. Pharmacokinetic drug evaluation of rifaximin for treatment of diarrhea-predominant irritable bowel syndrome.
Bruzzese E; Pesce M; Sarnelli G; Guarino A
Expert Opin Drug Metab Toxicol; 2018 Jul; 14(7):753-760. PubMed ID: 29897844
[TBL] [Abstract][Full Text] [Related]
13. Review article: potential mechanisms of action of rifaximin in the management of irritable bowel syndrome with diarrhoea.
Pimentel M
Aliment Pharmacol Ther; 2016 Jan; 43 Suppl 1():37-49. PubMed ID: 26618924
[TBL] [Abstract][Full Text] [Related]
14. Gut microbial signatures of patients with diarrhea-predominant irritable bowel syndrome and their healthy relatives.
Chen J; Lan H; Li C; Xie Y; Cheng X; Xia R; Ke C; Liang X
J Appl Microbiol; 2024 Jun; 135(6):. PubMed ID: 38849305
[TBL] [Abstract][Full Text] [Related]
15. [The effectiveness of a probiotic containing Bifidobacterium longum BB-46 and Enterococcus faecium ENCfa-68 in the treatment of post-infectious irritable bowel syndrome. Prospective randomized comparative study].
Yakovenko EP; Strokova TV; Ivanov AN; Iakovenko AV; Gioeva IZ; Aldiyarova MA
Ter Arkh; 2022 Feb; 94(2):180-187. PubMed ID: 36286741
[TBL] [Abstract][Full Text] [Related]
16. Increased Ileal Immunoglobulin A Production and Immunoglobulin A-Coated Bacteria in Diarrhea-Predominant Irritable Bowel Syndrome.
Liu Y; Yuan X; Li L; Lin L; Zuo X; Cong Y; Li Y
Clin Transl Gastroenterol; 2020 Mar; 11(3):e00146. PubMed ID: 32352710
[TBL] [Abstract][Full Text] [Related]
17. Fecal Microbiota in Patients with Irritable Bowel Syndrome Compared with Healthy Controls Using Real-Time Polymerase Chain Reaction: An Evidence of Dysbiosis.
Shukla R; Ghoshal U; Dhole TN; Ghoshal UC
Dig Dis Sci; 2015 Oct; 60(10):2953-62. PubMed ID: 25784074
[TBL] [Abstract][Full Text] [Related]
18. Characteristic dysbiosis of gut microbiota of Chinese patients with diarrhea-predominant irritable bowel syndrome by an insight into the pan-microbiome.
Wang Z; Xu CM; Liu YX; Wang XQ; Zhang L; Li M; Zhu SW; Xie ZJ; Wang PH; Duan LP; Zhu HQ
Chin Med J (Engl); 2019 Apr; 132(8):889-904. PubMed ID: 30958430
[TBL] [Abstract][Full Text] [Related]
19. Altered metabolism of bile acids correlates with clinical parameters and the gut microbiota in patients with diarrhea-predominant irritable bowel syndrome.
Wei W; Wang HF; Zhang Y; Zhang YL; Niu BY; Yao SK
World J Gastroenterol; 2020 Dec; 26(45):7153-7172. PubMed ID: 33362374
[TBL] [Abstract][Full Text] [Related]
20. Rifaximin for the treatment of diarrhea-predominant irritable bowel syndrome.
Kane JS; Ford AC
Expert Rev Gastroenterol Hepatol; 2016; 10(4):431-42. PubMed ID: 26753693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
